Homepage
An open letter in response to the GHA/CEO report on IMI
At IMI, we are always open to justified, balanced, and constructive criticism. We therefore read the report of Corporate Europe Observatory and Global Health Advocates with great interest. Although there are some valid points in the report, we regret the fact that the the authors target isolated challenges that IMI has faced and turn them into generalities in order to dismantle the integrity of the programme. IMI Executive Director Pierre Meulien highlights three of these in an open response to the report.
IMI2 – Calls 22 and 23: updated topics available and webinar registration open
IMI2 – Calls 22 and 23: updated topics available and webinar registration open moreIMI announces COVID projects, boosts funding pot to EUR 72 million
IMI announces COVID projects, boosts funding pot to EUR 72 million moreMeet the IMI projects already helping to fight COVID-19
Meet the IMI projects already helping to fight COVID-19 more
IMI BROCHURE HIGHLIGHTS PROJECT SUCCESSES
IMI projects are accelerating the medicines development process, generating new scientific insights, and developing resources for open use by the research community. Furthermore, some of our projects are already delivering direct benefits to patients. Interested in concrete numbers and examples? Find out more about the impact and outputs of our projects in our new brochure, and learn how we are 'Carrying the torch for medical innovation'.
WATCH IMI video
Carrying the torch for medical innovation
Diseases keep changing, and infections we treated for decades can once again kill. By bringing together researchers from the public and private sectors, we are working to speed up medicines development and turn knowledge into treatments. Watch our video and share it!